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Introduction: The purpose of this study was to assess the direct injection of bone marrow-derived
mesenchymal stem cells (BMSCs) suspended in hyaluronic acid (HA) combined with drilling as a
treatment for chondral defects in a canine model.
Methods: Tibial bone marrow was aspirated, and BMSCs were isolated and cultured. One 8.0-mm
diameter chondral defect was created in the femoral groove, and nine 0.9-mm diameter holes were
drilled into the defect. BMSCs (2.14  107 cells) suspended in HA were injected into the defect. HA alone
was injected into a similar defect on the contralateral knee as a control. Animals were sacriﬁced at 3 and
6 months.
Results: Although the percentage of coverage assessed macroscopically was signiﬁcantly better at 6
months than at 3 months in both the BMSC (p ¼ 0.02) and control (p ¼ 0.001) groups, there were no
signiﬁcant differences in the International Cartilage Repair Society grades. The Wakitani histological
score was signiﬁcantly better at 6 months than at 3 months in the BMSC and control groups. While the
control defects were mostly ﬁlled with ﬁbrocartilage, several of the defects in the BMSC group contained
hyaline-like cartilage. The mean Wakitani scores of the BMSC group improved from 7.0 ± 1.0 at 3 months
to 4.6 ± 0.9 at 6 months, and those of the control group improved from 9.4 ± 1.2 to 6.0 ± 0.6. The BMSC
group showed signiﬁcantly better regeneration than the control group at 3 months (p ¼ 0.04), but the
difference at 6 months was not signiﬁcant (p ¼ 0.06).
Conclusions: The direct injection of BMSCs in HA combined with drilling enhanced cartilage
regeneration.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Articular cartilage covers the ends of bones that form dia-
rthrodial joints and functions as a lubricant and shock absorber.
Articular cartilage is a histologically hyaline cartilage and contains
an abundant extracellular matrix that lacks blood, lymphatic, and
nerve supplies. These factors contribute to its poor repair potential.
Typically, the reparative tissue generated after an injury lacks the
biochemical capability to express certain cartilage-speciﬁc mole-
cules and shows a substantially reduced biomechanical durability
compared with normal hyaline cartilage [1]. Articular cartilagesting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. Phase-contrast micrograph of a culture of live bone marrow-derived mesen-
chymal stem cells released by harvesting with trypsineEDTA. Bar: 50 mm.
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radiological changes caused by articular cartilage defects show
progressiveworsening over more than 10 years [2,3]. Therefore, the
repair of articular cartilage defects is now thought to be essential
for preventing their progression to subsequent osteoarthritis.
Currently, the conventional treatment for articular cartilage
defects is a bone marrow stimulation technique, in which the
subchondral bone is perforated to facilitate cartilage repair by the
bone marrow-derived cells and growth factors present in blood [4].
However, after this procedure, the cartilage defects are most often
repaired with ﬁbrocartilage, which is biochemically and biome-
chanically different from normal hyaline cartilage. Over time,
ﬁbrocartilage undergoes degeneration [1]. The beneﬁts of autolo-
gous chondrocyte implantation (ACI) [5] and mosaicplasty [6e8]
have been reported over the last 20 years. Although small artic-
ular cartilage defects can be successfully repaired using these
techniques, normal cartilage tissue must be harvested for use.
Alternative methods for obtaining autologous cells that avoid such
tissue harvesting would be preferable.
Investigations into the repair of articular cartilage defects using
various types of cells have been performed around the world.
Osteochondral progenitor cells and mesenchymal stem cells exist
in many kinds of tissue, including bone marrow, synovium, muscle
and fat, and autologous cells can be easily obtained from these
tissues. Among these cell types, we have previously used bone
marrow-derived mesenchymal stem cells (BMSCs) as a cell source
to assess new methods for enhancing cartilage regeneration
involving the transplantation of autologous BMSCs into articular
cartilage defects. In 1994, we showed the effectiveness of BMSC
transplantation for the repair of osteochondral defects in a pre-
clinical study using the rabbit model [9]. Later, we found that BMSC
transplantation into chondral defects in a clinical trial in humans
resulted in better and longer-lasting good clinical outcomes
[10e12]. In another study, we compared BMSC transplantation
concomitant with high tibial osteotomy (HTO) with HTO alone to
determine the efﬁcacy of the BMSCs. Although the BMSC group
showed signiﬁcantly better arthroscopic and histological results
than the control group at the 16-month follow-up, the clinical re-
sults were not signiﬁcantly different between the groups [13]. This
trend was conﬁrmed at the 5- and 10-year follow-ups [14]. In
addition, we examined the records from all 41 patients (45 trans-
plantations) that we treated with this procedure, including the
cases mentioned above, from January 1998 to November 2008 until
their last visit to the clinic. No tumors or infections were observed
during the 5e137 months (mean: 75 months) of follow-up, indi-
cating that autologous BMSC transplantation is safe [15].
However, the techniques used in these basic and clinical studies
for BMSC transplantation, as well as ACI, required an arthrotomy to
place the stem cells in the defects. Recently, several authors have
reported less invasive methods, including intra-articular injections
for transplanting stem cells. Such procedures have contributed to
the effective regeneration of articular cartilage in animal models
[16e19].
The purpose of the present study was to assess the direct in-
jection of BMSCs suspended in hyaluronic acid (HA) combined with
bone marrow stimulation to treat chondral defects compared with
treatment with bone marrow stimulation and HA injection alone.
Our hypothesis was that injection of BMSCs suspended in HA and
bone marrow stimulation leads to better articular cartilage regen-
eration than bone marrow stimulation and HA alone.
2. Materials and methods
Fifteen male, 1-year-old beagle dogs (mean weight 10.4 (range:
9.8e11.6) kg, Oriental Yeast Co., Ltd., Tokyo, Japan), which were freeof musculoskeletal abnormalities, were used in this experiment.
The animals were housed in large cages for at least 1 week to ac-
climatize them to the surroundings, and they were provided food
and water ad libitum prior to the experiment. All experimental
animal procedures were approved by and conducted in accordance
with the regulations of the Osaka City University Graduate School
of Medicine Committee on Animal Research.2.1. Harvest of BMSC and culture
Under anesthesia induced by subcutaneous injection of keta-
mine (50 mg/mL; Sankyo, Tokyo, Japan) and xylazine (0.2 mg/mL;
Bayer HealthCare, Tokyo, Japan) at a ratio of 10:3 and a dose of
0.5 mL/kg body weight, 5 mL of bone marrow was aspirated from
the tibia using a bone marrow harvesting needle (SHEEN MAN Co.,
Ltd., Osaka, Japan) that was attached to a syringe containing 0.2 mL
of heparin (1000 units/mL). The aspirates were washed with Dul-
becco's modiﬁed Eagle's medium (Wako Pure Chemical Industries,
Ltd, Osaka, Japan) supplementedwith 15% fetal bovine serum (Gibco
Lab Inc., Grand Island, NY, USA), L-glutamine (SigmaeAldrich, St.
Louis, MO, USA), and penicillinestreptomycineamphotericin B
(SigmaeAldrich). Then, the aspirates were seeded onto 100-mm
culture dishes and incubated in a humidiﬁed 5% CO2e95% air
environment at 37 C. The medium was replaced every 2 days.
Approximately 10e14 days after seeding, the adherent cells, which
were nearly conﬂuent, were released from the dish by a 5-
min exposure to 0.25% trypsin and 0.02% ethylenediaminetetra-
acetic acid (EDTA). The cells were subcultured, and before the cells
approached conﬂuence again (Fig.1), theywere harvested using the
same methods described above. The mean cell count was
2.14 ± 0.42  107 (range: 0.2e2.8  107).
Concurrently with bone marrow aspiration, peripheral blood
was also drawn and the serumwas extracted from the whole blood
by centrifuging 5 mL of peripheral blood at 3500 rpm for 10 min.
The supernatant was extracted as autologous serum and frozen
at 80 C until use during the cell injection as a suspension
medium.2.2. Surgical protocol and cell injection
The dogs were anaesthetized as described above, and then the
kneewas exposed using a standardmedial parapatellar approach. A
full-thickness chondral defect was created in the patella groove of
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Industries Co., Ltd., Tokyo, Japan). The base of the defect was
smoothed with a small chisel. Next, nine holes were drilled into the
defect using a 0.9 mm diameter wire (ConMed Linvatec Bio-
materials, Ltd., Tampere, Finland) as bone marrow stimulation
(Fig. 2). Then, BMSCs suspended in 500 mL of autologous serum and
500 mL of puriﬁed 1% HA (ARTZ Dispo; Kaken Pharmaceutical Co.,
Ltd., Tokyo, Japan) were directly injected into the defect (drilling
and cells in HA: BMSC group). The same defect creation and drilling
was performed on the opposite knee joint, but HA and autologous
serum alone, i.e., without the BMSC transplantation, was injected as
a control (drilling, HA, and serum alone: control group). Finally, the
joint capsule and skinwere closed with 3-0 nylon sutures. Care was
taken to avoid any leakage of the injected solutions into the extra-
articular tissue during the procedure. All the dogs were returned to
their cages after the operation and allowed to move freely.
2.3. Evaluation
Five dogs were euthanized 3 months after the BMSC injection
and 10 dogs were euthanized 6 months after surgery using an
intravenous overdose of pentobarbital sodium (Nembutal, Dai-
nippon Pharmaceutical Co. Ltd., Osaka, Japan).
2.4. Macroscopic evaluation
The macroscopic tissue regeneration was evaluated as the per-
centage of coverage area using ImageJ software [20] and the In-
ternational Cartilage Repair Society (ICRS) score [21]. The ICRS
scoring system includes three categories: the degree of defect
repair, integration at the border zone, and the macroscopic
appearance, with a maximum score of 12 (best result). The degree
of defect repair was graded from 0 (0% repair of the defect depth) to
4 points (repair level with the surrounding cartilage). The inte-
gration at the border zone was graded from 0 (no contact to 25% of
the graft was integrated with the surrounding cartilage) to 4 points
(complete integration with the surrounding cartilage). The
macroscopic appearance was graded from 0 (total degeneration of
the grafted area) to 4 points (an intact smooth surface).
2.5. Histology
Each harvested knee was ﬁxed in 4% neutral formalin, decal-
ciﬁed in 0.5 M EDTA, dehydrated in a graded ethanol series, and
embedded in parafﬁn. The specimens were cut in the oblique
sagittal direction to 5-mm thickness with a microtome (Leica
Microsystems, Inc., Wetzlar, Germany) and stained with toluidineFig. 2. A full-thickness chondral defect was created in the femoral groove using an 8-
mm diameter disposable biopsy punch. The base of the defect was smoothed with a
surgical scalpel. Then, nine holes were drilled into the defect using 0.9 mm-diameter
wire as bone marrow stimulation.blue. The Wakitani histological scoring system [9] was used. This
scale includes ﬁve categories: cell morphology, matrix staining,
surface regularity, thickness of cartilage, and integration with the
adjacent host cartilage, with a maximum score of 14 (poorest
result). The cell morphology was graded from 0 (tissue that
appeared normal compared with the adjacent, uninjured cartilage)
to 4 points (cartilage tissue was absent). Matrix staining, or the
degree of metachromasia, was graded from 0 (tissue that appeared
normal compared with the adjacent, uninjured cartilage) to 3
points (no metachromatic staining). Surface regularity, or the pro-
portion of the defect surface that appeared smooth compared with
the entire surface, was graded from 0 (more than three quarters of
the surface was smooth) to 3 points (less than one quarter of the
surface was smooth). The thickness of cartilage, or the average
thickness of the cartilage in the defect compared with the sur-
rounding cartilage, was graded from 0 (the average thickness of the
repair tissue in the defect was more than two-thirds that of the
surrounding cartilage) to 2 points (the average thickness was less
than one-third that of the surrounding cartilage). Integration of the
repair tissue with the host cartilage was graded from 0 (no gap
between the repair tissue and host cartilage) to 2 points (a com-
plete lack of integration).
2.6. Statistical analysis
The total macroscopic and histological scores were compared
between the BMSC and control groups, as well as between 3 and 6
months after the operation within each group, using paired t-tests
and ManneWhitney U tests. P-values less than 0.05 were consid-
ered statistically signiﬁcant. The statistical analyses were per-
formed in Excel 2010 (Microsoft, Redmond, WA, USA).
3. Results
3.1. Macroscopic evaluation
No signs of osteoarthritis, such as osteophytes or cyst formation,
were found around the defect area. At 3 months, the defects in the
control group had very little covering. In contrast, the defects in the
BMSC groupwere partially coveredwith repair tissue. However, the
mound covering the drill holes remained visible because of the thin
repair tissue coverage. At 6 months, the defects in the control and
BMSC groups were ﬁlled with much more repair tissue than those
at 3 months, and the drilling scar was no longer visible (Fig. 3). The
mean percentage of coverage area in the control group was
32.4 ± 6.6% at 3 months and 62.8 ± 8.8% at 6 months, and of the
BMSC group was 44.8 ± 13.2% at 3 months and 64.7 ± 7.5% at 6
months. Although there were signiﬁcant differences between the
coverage areas at 3 months and 6 months in both the control
(p ¼ 0.001) and BMSC (p ¼ 0.02) groups, no signiﬁcant difference
was found between the control and BMSC groups at either 3 or 6
months (Fig. 4).
3.1.1. Comparison of ICRS scores at 3 and 6 months
The mean ICRS score of the control group was 2.8 ± 0.7 at 3
months and 4.4 ± 1.3 at 6 months (p ¼ 0.13), and that of the BMSC
group was 4.0 ± 1.2 at 3 months and 5.5 ± 1.7 at 6 months
(p ¼ 0.29). Although the ICRS scores at 6 months appeared better
than those at 3 months, no signiﬁcant difference was found be-
tween the 3 and 6 month data in either group (Fig. 5).
3.1.2. Comparison of ICRS scores between the BMSC and control
groups
The mean ICRS score at 3 months was 2.8 ± 0.7 in the control
group and 4.0± 1.2 in the BMSC group (p¼ 0.07), and the ICRS score
Fig. 3. Macroscopic images of the A) 3 M control, B) 3 M BMSC, C) 6 M control, and D)
6 M BMSC groups. There were no signs of osteoarthritis, such as osteophytes or cyst
formation, around the defect area. At 3 months, the defects in the control group
showed no coverage with repair tissue. The defects in the BMSC group were covered by
a little repair tissue. However, the scar from the drilling remained visible. At 6 months,
the defects in the control and BMSC groups were ﬁlled with much more repair tissue
than those at 3 months, and the scar from drilling was no longer visible. Moreover, the
defect coverage in the BMSC group appeared better than that in the control group.
Fig. 5. Mean ICRS scores of the control and BMSC groups were 2.8 ± 0.7 and 4.0 ± 1.2 at
3 months and 4.4 ± 1.3 and 5.5 ± 1.7 at 6 months. No signiﬁcant differences were found
between the 3 and 6 month data in the control (p ¼ 0.13) or BMSC (p ¼ 0.29) groups or
between the control and BMSC groups at 3 (p ¼ 0.07) or 6 (p ¼ 0.10) months.
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BMSC group (p¼ 0.09). Although the ICRS scores in the BMSC group
appeared better than those in the control group, no signiﬁcant
differencewas found between the control and BMSC groups (Fig. 5).3.2. Histology
At 3 months, although the defects were partially ﬁlled with a
ﬁbrous tissue at the drilling sites, most of the control specimens
contained no cartilage tissue (Fig. 6A and E). In the BMSC group, the
defects were partially ﬁlled with a hyaline-like cartilage repairFig. 4. Mean percentage of coverage area in the control group was 32.4 ± 6.6% at 3
months and 62.8 ± 8.8% at 6 months, and that of the BMSC group was 44.8 ± 13.2% at 3
months and 64.7 ± 7.5% at 6 months. Although there were signiﬁcant differences
between the coverage areas at 3 and 6 months in both the control (p ¼ 0.001) and
BMSC (p ¼ 0.02) groups, no signiﬁcant difference was found between the control and
BMSC groups at either 3 or 6 months.tissue originating from the drilling site, and a portion of the re-
generated tissue extended and connected to the normal cartilage
(Fig. 6B and F). At 6 months, although the amount of repair tissue
ﬁlling the defects in the control group was markedly better than
that at 3 months, the tissue consisted of ﬁbrocartilage showing
little metachromasia (Fig. 6C and G). In the BMSC group, the
regeneration occurred not only at the drilling site, but also at the
site adjacent to the normal cartilage that was not drilled, indicating
better repair than that found at 3months. Moreover, portions of the
tissue appeared similar to hyaline-like cartilage and showed qual-
itative improvements in metachromasia, surface regularity, and
repair tissue thickness compared with the control group (Fig. 6D
and H).3.2.1. Comparison of Wakitani scores at 3 with 6 months
The mean Wakitani score of the control group was 9.4 ± 1.2 at 3
months and 6.0 ± 0.6 at 6 months (p ¼ 0.0002), and that of the
BMSC group was 7.0 ± 1.0 at 3 months and 4.6 ± 0.9 at 6 months
(p ¼ 0.01). The histological regeneration at 6 months was signiﬁ-
cantly better than that at 3 months in both groups (Fig. 7).3.2.2. Comparison of Wakitani scores in the BMSC and control
groups
The mean Wakitani score at 3 months was 9.4 ± 1.2 in the
control group and 7.0 ± 1.0 in the BMSC group (p ¼ 0.04), and the
Wakitani score at 6 months was 6.0 ± 0.6 in the control group and
4.6 ± 0.9 in the BMSC group (p ¼ 0.06). Although the BMSC group
showed better regeneration than the control group at 3 months, no
signiﬁcant difference was found between the control and BMSC
groups at 6 months (Fig. 7).4. Discussion
The effects of treating chondral defects using the direct injection
of BMSCs in HAwere assessed in this study. The results suggest that
the direct injection of BMSCs suspended in HA combined with bone
marrow stimulation as a treatment for chondral defects in the
femoral groove signiﬁcantly improves cartilage regeneration
compared with that achieved in the bone marrow stimulation and
HA injection alone control group, as assessed by histological ex-
amination using the Wakitani score at 3 months. Although there
was no signiﬁcant difference between the control and BMSC groups
at 6 months, the p-value (0.06) was nearly signiﬁcant. Including
Fig. 6. Histology of the repair tissue in the A), D) control group at 3 months (Wakitani score: 10); B), E) BMSC group at 3 months (Wakitani score: 7); C), F) control group at 6 months
(Wakitani score: 5); and D), G) BMSC group at 6 months (Wakitani score: 3). Upper row bar: 1.0 mm; lower row shows magniﬁcations of the framed areas in each panel of the upper
row, bar: 100 mm. At 3 months, although the defects were partially ﬁlled with a ﬁbrous tissue at the drilling sites, most of the control specimens contained no cartilage tissue (A, E).
In the BMSC group, the defects were partially ﬁlled with a hyaline-like cartilage repair tissue originating from the drilling site, and a portion of the regenerated tissue extended and
connected to the normal cartilage (B, F). At 6 months, although markedly more repair tissue was found ﬁlling the defects in the control group than that at 3 months, the tissue
consisted of ﬁbrocartilage showing little metachromasia (C, G). In the BMSC group, the regeneration at 6 months occurred not only at the drilling site, but also at the sites adjacent to
normal cartilage that were not drilled and was better than that found at 3 months. Moreover, portions of the tissue appeared similar to hyaline-like cartilage and showed qualitative
improvements in metachromasia, surface regularity, and repair tissue thickness compared with those in the control group (D, H).
Fig. 7. Mean Wakitani scores of the control group and the BMSC group were 9.4 ± 1.2
and 7.0 ± 1.0 at 3 months and 6.0 ± 0.6 and 4.6 ± 0.9 at 6 months. Both the control and
BMSC groups showed signiﬁcantly better regeneration at 6 months than at 3 months
(control: p ¼ 0.0002; BMSC: p ¼ 0.01). The BMSC group showed signiﬁcantly better
regeneration than the control group at 3 months (p ¼ 0.04), but those differences were
not signiﬁcant at 6 months (p ¼ 0.06).
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achieve a signiﬁcant difference.
We used drilling as a bone marrow stimulation technique
together with transplantation of BMSCs in HA to enhance the
healing potential of cartilage. Bone marrow stimulation creates
channels through the subchondral bone that allow blood and bone
marrow elements, including the mesenchymal stem cells that
contribute to cartilage healing, access to the damaged surface [4].
The histologic results shown here indicate that chondral repair
mainly occurred in the drilled sites at 3 months, but repair was
found even in the non-drilled sites at 6 months. Agung et al. re-
ported that injected green ﬂuorescent protein-labeled BMSCs had
an afﬁnity for damaged joint tissues, localizing and participating in
the repair of damaged cartilage lesions [16]. In addition, Caplan andDennis [22] reported that BMSCs have the potential not only to
differentiate into several mesenchymal phenotypes, such as oste-
oblasts, chondrocytes, myocytes, marrow stromal cells, tendon-
ligament ﬁbroblasts, and adipocytes, but also to secrete a variety
of cytokines and growth factors. These factors have both paracrine
and autocrine effects, including the suppression of the local im-
mune system and apoptosis and the inhibition of ﬁbrosis, as well as
the stimulation of mitosis and the differentiation of stem cells [22].
Based on the present results and those from previous reports,
BMSCs appear to contribute directly to cartilage repair by differ-
entiating into target cells that synthesize new tissue and contribute
indirectly by enhancing the effects of the endogenous BMSCs.
Several previous reports have shown the efﬁcacy of intra-
articular BMSC injection for chondral defect repair. McIlwraith
et al. demonstrated the beneﬁts of the intra-articular injection of
BMSCs combined with microfracture compared with microfracture
alone for treating full-thickness defects in equine medial femoral
condyles. The arthroscopic and gross evaluations showed a trend
for better overall repair tissue quality in the BMSC-treated joints,
and the immunohistochemical analysis also showed signiﬁcantly
higher levels of aggrecan in the BMSC injection group after 12
months [18]. Nam et al. reported that the intra-articular injection of
BMSCs combined with drilling enhanced the healing of full-
thickness chondral defects signiﬁcantly more than the drilling
alone control in a caprine model, as assessed by macroscopic ICRS
scoring, histological O'Driscoll scoring, and immunohistochemical
analyses including glycosaminoglycan content and chondrogenic
gene expression of aggrecan, collagen II, and Sox9 [19]. In the
present study, we used beagle dogs and created an 8.0 mm diam-
eter chondral defect and drilled nine 0.9-mm diameter holes in the
femoral groove, not in the medial condyle, before injecting
approximately 2.14  107 BMSCs suspended in HA.
This unique protocol was used in the present study because
the injection of BMSCs, HA, and autologous serum, as well as
the drilling technique, were all performed for the chondral defect.
Nam et al. performed drilling and BMSC transplantation
without HA, while McIlwraith et al. performed drilling and BMSC
S. Yamasaki et al. / Regenerative Therapy 2 (2015) 42e48 47transplantation with HA, but without serum. HA may improve
cartilage healing by coating the cartilage surface and localizing in
the cartilage extracellular matrix among the collagen ﬁbrils and
proteoglycans [23], increasing synovial cell migration [24]. These
effects may explain why the histological score of the control group
was improved at 6 months compared with that at 3 months after
surgery in the present study. However, the repair tissue created in
the control group was mainly ﬁbrocartilaginous, similar to the re-
sults of previous reports [25e27]. Therefore, BMSCs are likely
essential for achieving cartilage repair. Regarding the effects of
autologous serum, IL-1 is the most potent known mediator of
cartilage loss. Autologous serum is an effective treatment for
osteoarthritis because it contains IL-1 receptor antagonist. There-
fore, even the control group in the present study had a certain
potential for chondral repair [28]. Moreover, the repair was evalu-
ated in the present study using quantitative measures for the
macroscopic and histologic ﬁndings that were different than those
used by McIlwraith et al.
One limitation of the present study is that the regeneration of
the chondral defects using the BMSC did not achieve a completely
normal articular cartilage. We did not induce chondrogenic differ-
entiation of the BMSCs before injection in this experiment. Ac-
cording to Marquass et al., chondrogenically predifferentiated
BMSCs lead to better chondral regeneration than undifferentiated
BMSCs [29]. In addition, several studies have reported that exoge-
nous basic ﬁbroblast growth factor-2 accelerates cartilage repair
[30e34]. Another limitation is that we used a canine model in this
study, which may demonstrate different cartilage regeneration
properties than those that occur in humans. In humans, a few
relevant clinical case reports [35e37] and one prospective, ran-
domized controlled clinical study [38] have been reported. Wong
et al. demonstrated that the intra-articular injection of cultured
BMSCs improves both the short-term clinical and MRI outcomes in
patients undergoing HTO and microfracture for varus knees with
cartilage defects. However, these clinical reports included patients
with knee osteoarthritis, not focal chondral defects. Further work
establishing clinical trials for the intra-articular injection of BMSCs
to treat human chondral defects is needed.
In conclusion, we demonstrated that the direct injection of
BMSCs suspended in HA combined with bone marrow stimulation
for treating chondral defects in the femoral groove appeared to
improve cartilage regeneration compared with bone marrow
stimulation and HA injection alone controls based on macroscopic
and histologic ﬁndings. The histological results showed that BMSC
injection signiﬁcantly enhanced chondral regeneration beyond
what was found in the control group at 3 months.Conﬂict of interest
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